NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates

Core Insights - NeoGenomics reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, but down from $0.05 per share a year ago, resulting in an earnings surprise of +50.00% [1] - The company generated revenues of $187.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.27% and increasing from $167.82 million year-over-year [2] - NeoGenomics shares have declined approximately 38.4% year-to-date, contrasting with the S&P 500's gain of 16.9% [3] Earnings Outlook - The future performance of NeoGenomics stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $189.51 million, and for the current fiscal year, it is $0.09 on revenues of $722.29 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5]